From modest beginnings 20 years ago as a niche contract research business, Neem Biotech has come of age. What started out with R&D around a neem tree and its medicinal purposes has now grown into a drug discovery company, focused on combating antibacterial resistance. Today, we discover novel assets and de-risk them by taking them up to the pre-clinical development stage before spinning them out into subsidiaries focused on distinct therapeutic applications. To fully leverage our unique position in antimicrobial R&D, we are undertaking an exciting anti-virulence approach to discover novel small molecules by utilising our expertise in bacterial-host interactions and coupling this with the exciting approach of fragment screening to discover novel compound programs.